Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.

Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ, Gontero P.

Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6. Review.

PMID:
29523366
2.

Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.

Cumberbatch MG, Catto JWF.

Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007-2. doi: 10.1016/j.eururo.2017.11.022. [Epub ahead of print] No abstract available.

PMID:
29221661
3.

Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.

Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, Lenaghan C, McEwen R, Bradford J, Polanski R, Ellston R, Avivar-Valderas A, Pilling J, Staniszewska A, Cumberbatch M, Critchlow SE, Cruzalegui F, Barry ST.

Clin Cancer Res. 2017 Dec 15;23(24):7584-7595. doi: 10.1158/1078-0432.CCR-17-0676. Epub 2017 Oct 2.

PMID:
28972046
4.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

Poon E, Mullins S, Watkins A, Williams GS, Koopmann JO, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, Wilkinson RW.

J Immunother Cancer. 2017 Aug 15;5(1):63. doi: 10.1186/s40425-017-0268-8.

5.

Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.

Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L.

Eur Urol. 2017 Dec;72(6):869-885. doi: 10.1016/j.eururo.2017.06.035. Epub 2017 Jul 27. Review.

PMID:
28757301
6.

The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet.

Cumberbatch MG, Catto JW.

Eur Urol Focus. 2016 Dec;2(5):467-468. doi: 10.1016/j.euf.2016.09.001. Epub 2016 Sep 15.

PMID:
28723507
7.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
8.

E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks.

Bourke L, Bauld L, Bullen C, Cumberbatch M, Giovannucci E, Islami F, McRobbie H, Silverman DT, Catto JWF.

Eur Urol. 2017 Jun;71(6):915-923. doi: 10.1016/j.eururo.2016.12.022. Epub 2017 Jan 7. Review.

PMID:
28073600
9.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.

Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

PMID:
27568654
10.

The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years.

Cumberbatch MG, Windsor-Shellard B, Catto JW.

BJU Int. 2017 Jan;119(1):100-109. doi: 10.1111/bju.13561. Epub 2016 Jul 26. Review.

11.

Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?

Cumberbatch MG, Catto JW.

Eur Urol. 2016 Oct;70(4):621-622. doi: 10.1016/j.eururo.2016.04.007. Epub 2016 Apr 29. No abstract available.

PMID:
27140723
12.

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.

Hudson K, Hancox UJ, Trigwell C, McEwen R, Polanska UM, Nikolaou M, Morentin Gutierrez P, Avivar-Valderas A, Delpuech O, Dudley P, Hanson L, Ellston R, Jones A, Cumberbatch M, Cosulich SC, Ward L, Cruzalegui F, Green S.

Mol Cancer Ther. 2016 May;15(5):877-89. doi: 10.1158/1535-7163.MCT-15-0687. Epub 2016 Feb 2.

13.

Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis.

Cumberbatch MG, Cox A, Teare D, Catto JW.

JAMA Oncol. 2015 Dec;1(9):1282-90. doi: 10.1001/jamaoncol.2015.3209. Review. Erratum in: JAMA Oncol. 2015 Dec;1(9):1224.

PMID:
26448641
15.

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.

Cumberbatch MG, Rota M, Catto JW, La Vecchia C.

Eur Urol. 2016 Sep;70(3):458-66. doi: 10.1016/j.eururo.2015.06.042. Epub 2015 Jul 3. Review.

PMID:
26149669
16.

Luzp4 defines a new mRNA export pathway in cancer cells.

Viphakone N, Cumberbatch MG, Livingstone MJ, Heath PR, Dickman MJ, Catto JW, Wilson SA.

Nucleic Acids Res. 2015 Feb 27;43(4):2353-66. doi: 10.1093/nar/gkv070. Epub 2015 Feb 6.

17.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

18.

Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C, Kim ES, Su X, Fan S, Gray N, Blowers DP, Wistuba II, Womack C.

Clin Cancer Res. 2014 Feb 1;20(3):595-603. doi: 10.1158/1078-0432.CCR-13-1638. Epub 2013 Nov 27.

19.

Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype.

Angell HK, Gray N, Womack C, Pritchard DI, Wilkinson RW, Cumberbatch M.

Br J Cancer. 2013 Sep 17;109(6):1618-24. doi: 10.1038/bjc.2013.487. Epub 2013 Aug 20.

20.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

21.

No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis.

Shaw FL, Kimber I, Begum R, Cumberbatch M, Dearman RJ, Griffiths CE.

Clin Exp Dermatol. 2012 Jan;37(1):40-7. doi: 10.1111/j.1365-2230.2011.04172.x. Epub 2011 Sep 20.

22.

Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis.

Shaw FL, Cumberbatch M, Kleyn CE, Begum R, Dearman RJ, Kimber I, Griffiths CE.

J Invest Dermatol. 2010 Jul;130(7):1940-2. doi: 10.1038/jid.2010.57. Epub 2010 Mar 18. No abstract available.

23.

The cutaneous biochemical redox barrier: a component of the innate immune defenses against sensitization by highly reactive environmental xenobiotics.

Pickard C, Louafi F, McGuire C, Lowings K, Kumar P, Cooper H, Dearman RJ, Cumberbatch M, Kimber I, Healy E, Friedmann PS.

J Immunol. 2009 Dec 1;183(11):7576-84. doi: 10.4049/jimmunol.0901064. Epub 2009 Nov 4.

24.

Langerhans cell migration: not necessarily always at the center of the skin sensitization universe.

Kimber I, Cumberbatch M, Dearman RJ.

J Invest Dermatol. 2009 Aug;129(8):1852-3. doi: 10.1038/jid.2009.54.

25.

Synergistic effects of chemical insult and toll-like receptor ligands on dendritic cell activation.

Dearman RJ, Cumberbatch M, Portsmouth C, Maxwell G, Basketter DA, Kimber I.

Toxicol In Vitro. 2008 Dec;22(8):1927-34. doi: 10.1016/j.tiv.2008.09.012. Epub 2008 Sep 23.

PMID:
18848616
26.

Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells.

Dearman RJ, Cumberbatch M, Maxwell G, Basketter DA, Kimber I.

Immunology. 2009 Apr;126(4):475-84. doi: 10.1111/j.1365-2567.2008.02922.x. Epub 2008 Sep 4.

27.

The effects of acute social stress on epidermal Langerhans' cell frequency and expression of cutaneous neuropeptides.

Kleyn CE, Schneider L, Saraceno R, Mantovani C, Richards HL, Fortune DG, Cumberbatch M, Dearman RJ, Terenghi G, Kimber I, Griffiths CE.

J Invest Dermatol. 2008 May;128(5):1273-9. Epub 2007 Nov 8.

28.

IL-18 is a key proximal mediator of contact hypersensitivity and allergen-induced Langerhans cell migration in murine epidermis.

Antonopoulos C, Cumberbatch M, Mee JB, Dearman RJ, Wei XQ, Liew FY, Kimber I, Groves RW.

J Leukoc Biol. 2008 Feb;83(2):361-7. Epub 2007 Nov 5.

PMID:
17984289
29.

Proteomic analysis of suction blister fluid isolated from human skin.

Macdonald N, Cumberbatch M, Singh M, Moggs JG, Orphanides G, Dearman RJ, Griffiths CE, Kimber I.

Clin Exp Dermatol. 2006 May;31(3):445-8.

PMID:
16681597
30.

Impaired Langerhans cell migration in psoriasis.

Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE.

J Exp Med. 2006 Apr 17;203(4):953-60. Epub 2006 Mar 27.

31.

Cytokines and Langerhans cell mobilisation in mouse and man.

Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I.

Cytokine. 2005 Oct 21;32(2):67-70. Epub 2005 Sep 8. Review.

PMID:
16153855
32.

Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment.

Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Betts CJ, Cumberbatch M, Dearman RJ, Kimber I.

Toxicol Sci. 2005 Nov;88(1):4-11. Epub 2005 Jul 13. Review.

PMID:
16014741
33.

Impact of cutaneous IL-10 on resident epidermal Langerhans' cells and the development of polarized immune responses.

Cumberbatch M, Clelland K, Dearman RJ, Kimber I.

J Immunol. 2005 Jul 1;175(1):43-50.

34.

Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation.

Dearman RJ, Bhushan M, Cumberbatch M, Kimber I, Griffiths CE.

Exp Dermatol. 2004 Jul;13(7):452-60.

PMID:
15217366
35.

Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin.

Bhushan M, Cumberbatch M, Dearman RJ, Kimber I, Griffiths CE.

Br J Dermatol. 2004 Jun;150(6):1217-8. No abstract available.

PMID:
15214919
36.

Dendritic cells and skin sensitisation hazard assessment.

Kimber I, Cumberbatch M, Betts CJ, Dearman RJ.

Toxicol In Vitro. 2004 Apr;18(2):195-202. Review.

PMID:
14757110
37.

Epidermal Langerhans cell migration and sensitisation to chemical allergens.

Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I.

APMIS. 2003 Jul-Aug;111(7-8):797-804. Review.

PMID:
12974781
38.

IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin.

Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CE.

Clin Exp Immunol. 2003 May;132(2):352-9.

39.

Assessment of glycosylation-dependent cell adhesion molecule 1 as a correlate of allergen-stimulated lymph node activation.

Betts CJ, Moggs JG, Caddick HT, Cumberbatch M, Orphanides G, Dearman RJ, Ryan CA, Hulette BC, Frank Gerberick G, Kimber I.

Toxicology. 2003 Mar 14;185(1-2):103-17.

PMID:
12505449
40.

Danger signals and skin sensitization.

Kimber I, Cumberbatch M, Dearman RJ, Griffiths CE.

Br J Dermatol. 2002 Sep;147(3):613-4. No abstract available.

PMID:
12207617
41.

Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity.

Conley RK, Cumberbatch MJ, Mason GS, Williamson DJ, Harrison T, Locker K, Swain C, Maubach K, O'Donnell R, Rigby M, Hewson L, Smith D, Rupniak NM.

J Neurosci. 2002 Sep 1;22(17):7730-6.

42.

Differential regulation of epidermal langerhans cell migration by interleukins (IL)-1alpha and IL-1beta during irritant- and allergen-induced cutaneous immune responses.

Cumberbatch M, Dearman RJ, Groves RW, Antonopoulos C, Kimber I.

Toxicol Appl Pharmacol. 2002 Jul 15;182(2):126-35.

PMID:
12140176
43.

The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits.

Mason GS, Cumberbatch MJ, Hill RG, Rupniak NM.

Can J Physiol Pharmacol. 2002 Apr;80(4):264-8.

PMID:
12025959
44.
45.

Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation.

Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE.

Biochem Cell Biol. 2002;80(1):103-7.

PMID:
11911118
46.

Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing.

Bhushan M, Cumberbatch M, Dearman RJ, Andrew SM, Kimber I, Griffiths CE.

Br J Dermatol. 2002 Jan;146(1):32-40.

PMID:
11841364
47.

Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.

Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, Cumberbatch MJ, Rupniak NM, Seabrook GR.

Neuroscience. 2002;109(3):609-17.

PMID:
11823070
48.

Alternative approaches to the identification and characterization of chemical allergens.

Kimber I, Pichowski JS, Betts CJ, Cumberbatch M, Basketter DA, Dearman RJ.

Toxicol In Vitro. 2001 Aug-Oct;15(4-5):307-12. Review.

PMID:
11566554
49.

Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats.

Williamson DJ, Shepheard SL, Cook DA, Hargreaves RJ, Hill RG, Cumberbatch MJ.

Br J Pharmacol. 2001 Jul;133(6):807-14.

50.

Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism.

Cumberbatch M, Dearman RJ, Antonopoulos C, Groves RW, Kimber I.

Immunology. 2001 Mar;102(3):323-30.

Supplemental Content

Loading ...
Support Center